Haemophilia: trials for referral
143 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
143 trials shown
Phase 1/214 sites
RecruitingCanada, Spain, Italy, New Zealand, Poland, United States
NCT05987449
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Hoffmann-La Roche
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 373 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Canada
NCT07416604
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Hoffmann-La Roche
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingChina
NCT03961243
Lentiviral FIX Gene Therapy
Shenzhen Geno-Immune Medical Institute
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingChina
NCT03217032
Lentiviral FVIII Gene Therapy
Shenzhen Geno-Immune Medical Institute
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 383 sites
RecruitingArgentina, Australia, Brazil, Canada, Germany, Denmark
NCT07830732
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
Novo Nordisk A/S
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingSingapore
NCT07787091
A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A
Arditus Pte Ltd
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 343 sites
RecruitingBelgium, Brazil, Canada, China, Germany, Spain
NCT07285460
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Sanofi
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 382 sites
RecruitingArgentina, Austria, Australia, Brazil, Canada, China
NCT05145127
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Pfizer
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 343 sites
RecruitingArgentina, Austria, Brazil, Switzerland, China, Germany
NCT07416526
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Hoffmann-La Roche
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 1/255 sites
RecruitingAustralia, Brazil, Canada, Germany, Spain, France
NCT06379789
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Regeneron Pharmaceuticals
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 317 sites
RecruitingAustria, Australia, Belgium, Spain, France, United Kingdom
NCT07080905
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
CSL Behring
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07838194
Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children
Hoffmann-La Roche
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07876674
A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia
Shanghai RAAS Blood Products Co., Ltd.
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 414 sites
RecruitingCanada, Japan, Taiwan, United States
NCT06941870
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Sanofi
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingIndia, United States
NCT06703606
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Pfizer
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 363 sites
RecruitingArgentina, Austria, Australia, Brazil, Canada, China
NCT05611801
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Pfizer
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 1/26 sites
RecruitingUnited States
NCT07226206
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Hoffmann-La Roche
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govPhase 24 sites
RecruitingJapan
NCT07681089
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Kiminori Kimura, MD
Registry updated 5 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingChina
NCT07847697
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10
Sinocelltech Ltd.
Registry updated 29 Sept 2026
Registry record: ClinicalTrials.govPhase 48 sites
RecruitingSpain, Italy, Taiwan, United States
NCT06145373
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Sanofi
Registry updated 23 Sept 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 133 sites
RecruitingAustria, Belgium, Switzerland, Germany, Spain, France
NCT07220564
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Novo Nordisk A/S
Registry updated 18 Sept 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingChina
NCT07789587
A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Registry updated 27 Aug 2026
Registry record: ClinicalTrials.govPhase 332 sites
RecruitingAustralia, Bulgaria, Brazil, Canada, Hong Kong, Israel
NCT06003387
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
CSL Behring
Registry updated 27 Aug 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingChina
NCT07788469
A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Registry updated 26 Aug 2026
Registry record: ClinicalTrials.govPhase 41 site
Not yet recruitingUnited States
NCT07158606
Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction
Versiti Blood Health
Registry updated 27 Jul 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingCanada, United States
NCT06349473
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Equilibra Bioscience LLC
Registry updated 2 Jul 2026
Registry record: ClinicalTrials.govPhase 1/29 sites
RecruitingChina
NCT07644832
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
Shanghai RAAS Blood Products Co., Ltd.
Registry updated 12 Jun 2026
Registry record: ClinicalTrials.govPhase 416 sites
RecruitingSwitzerland, Germany, Spain, Finland, France, United Kingdom
NCT05936580
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
Octapharma
Registry updated 12 May 2026
Registry record: ClinicalTrials.govPhase 418 sites
RecruitingGermany, Spain, Finland, France, United Kingdom, Croatia
NCT05935358
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Octapharma
Registry updated 12 May 2026
Registry record: ClinicalTrials.govPhase 31 site
RecruitingChina
NCT07545395
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Suzhou Alphamab Co., Ltd.
Registry updated 22 Apr 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States41 open trials
- Spain32 open trials
- China30 open trials
- Germany29 open trials
- France26 open trials
- Italy23 open trials
- Canada19 open trials
- United Kingdom18 open trials
- Türkiye13 open trials
- Japan12 open trials
- Brazil11 open trials
- Austria11 open trials
- Denmark11 open trials
- Taiwan10 open trials
- South Korea10 open trials
- Belgium9 open trials
- Australia9 open trials
- Netherlands8 open trials
- Sweden8 open trials
- Poland7 open trials
- Israel7 open trials
- South Africa7 open trials
- India7 open trials
- Croatia7 open trials
- Switzerland7 open trials
- Finland7 open trials
- Argentina6 open trials
- Greece6 open trials
- Hungary5 open trials
- Mexico5 open trials
- Czechia5 open trials
- Norway5 open trials
- Saudi Arabia4 open trials
- Portugal4 open trials
- Bulgaria4 open trials
- Ireland3 open trials
- Romania3 open trials
- Serbia3 open trials
- Slovakia3 open trials
- Russia3 open trials
- Thailand3 open trials
- Lithuania3 open trials
- New Zealand2 open trials
- Malaysia2 open trials
- Singapore2 open trials
- Hong Kong2 open trials
- Belarus2 open trials
- Estonia2 open trials
- Egypt2 open trials
- Oman1 open trial
- Uruguay1 open trial
- North Macedonia1 open trial
- Bangladesh1 open trial
- Colombia1 open trial
- Iran1 open trial
- Chile1 open trial
- Azerbaijan1 open trial
- Slovenia1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Amsterdam UMC Location University of Amsterdam
Amsterdam, Netherlands
5 trials · 27 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
26 trials · 67 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Stopped early
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
NCT04563520 · Phase 3 · United States
Source: ClinicalTrials.govOpened for recruitment
NCT07220564 · Phase 1 · Austria, Belgium, Switzerland, Germany, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT06716814 · Phase 3 · Bulgaria, Germany, Spain, France, Greece, Italy
Source: ClinicalTrials.govPhase changed: Phase 1 → Phase 4
NCT06145373 · Phase 4 · Spain, Italy, Taiwan, United States
Source: ClinicalTrials.govOpened for recruitment
NCT06145373 · Phase 4 · Spain, Italy, Taiwan, United States
Source: ClinicalTrials.govOpened for recruitment
NCT05962398 · Phase 2/3 · Belgium, Germany, Denmark, United Kingdom, Ireland, Netherlands
Source: ClinicalTrials.govOpened for recruitment
NCT05768386 · Phase 4 · Australia, Belgium, Brazil, Germany, Spain, France
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05181618 · Phase 4 · Brazil, Canada, Germany, Spain, United Kingdom, Hungary
Source: ClinicalTrials.govClosed for recruitment
NCT06145373 · Phase 4 · Spain, Italy, Taiwan, United States
Source: ClinicalTrials.govClosed for recruitment
NCT05768386 · Phase 4 · Australia, Belgium, Brazil, Germany, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT05962398 · Phase 2/3 · Belgium, Germany, Denmark, United Kingdom, Ireland, Netherlands
Source: ClinicalTrials.govOpened for recruitment
NCT06716814 · Phase 3 · Bulgaria, Germany, Spain, France, Greece, Italy
Source: ClinicalTrials.govClosed for recruitment
NCT07220564 · Phase 1 · Austria, Belgium, Switzerland, Germany, Spain, France
Source: ClinicalTrials.govNew in the registry
Safety of Intraosseous Anaesthesia in Children With Haemophilia
NCT07916467 · No phase
Source: ClinicalTrials.govPhase changed: No phase → Phase 4
NCT05768386 · Phase 4 · Australia, Belgium, Brazil, Germany, Spain, France
Source: ClinicalTrials.govPhase changed: No phase → Phase 2/3
NCT05962398 · Phase 2/3 · Belgium, Germany, Denmark, United Kingdom, Ireland, Netherlands
Source: ClinicalTrials.govPhase changed: No phase → Phase 1/2
Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
NCT05360706 · Phase 1/2 · Germany, Netherlands
Source: ClinicalTrials.govPhase changed: No phase → Phase 4
Treatment of Hemophilia A Patients With FVIII Inhibitors
NCT04023019 · Phase 4 · Bulgaria, Germany, Spain, Finland, Croatia, Norway
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 3Ended 23 Sept 2026
Completed62 participants
NCT06738485
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
No phaseEnded 15 Sept 2026
Completed58 participants
NCT07736976
Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers
Phase 1/2Ended 15 Sept 2026
Completed11 participants
NCT03588299
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
Phase 3Ended 14 Sept 2026
Completed281 participants
NCT03754790
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
No phaseEnded 25 Aug 2026
Completed31 participants
NCT07425327
Validity and Reliability of the Two-minute Step Test in Hemophilia
Phase 2/3Ended 4 Aug 2026
Completed32 participants
NCT03974113
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Phase 2Ended 23 Jul 2026
Stopped early21 participants
NCT03307980
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
Reason given: The study was terminated early due to Sponsor and participants may transition into a long-term follow-up study. The decision to terminate the trial was not based on any safety and/or efficacy concerns.
No phaseEnded 11 Jul 2026
No phaseEnded 10 Jul 2026
Phase 3Ended 7 Jul 2026
Early Phase 1Ended 1 Jul 2026
Withdrawn before start0 participants
NCT06345833
Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
Reason given: Lack of Participants
No phaseEnded 17 Jun 2026
Stopped early13 participants
NCT04628871
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Reason given: Sangamo declared Chapter 11 Bankruptcy on 23Jun2026 and terminated the study on 21Jul2026.
No phaseEnded 16 Jun 2026
Stopped early19 participants
NCT06702579
Home Monitoring in Hemophilia A
Reason given: The study was discontinued due to a lack of available personnel to complete the study
Phase 3Ended 2 Jun 2026
Completed93 participants
NCT05817812
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
Phase 3Ended 2 Jun 2026
Phase 1/2Ended 29 May 2026
Stopped early5 participants
NCT06611436
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
Reason given: The study was terminated due to a strategic business decision and not due to safety concerns
Phase 1Ended 21 May 2026
Completed36 participants
2023-505801-17-00
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A
Phase 1Ended 21 May 2026
Completed24 participants
NCT06579144
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
No phaseEnded 4 May 2026
Completed427 participants
NCT04293523
A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
No phaseEnded 1 May 2026
Paused40 participants
NCT06273865
Version Testing of EnzySystem Version A for Hemophilia A
Reason given: Performing interim analysis before continuing with next center
Show more
No phaseEnded 30 Apr 2026
Completed123 participants
NCT05621746
An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct
Phase 1/2Ended 20 Apr 2026
Completed10 participants
NCT04684940
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
No phaseEnded 15 Apr 2026
Completed18 participants
NCT07187661
Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
Phase 1/2Ended 26 Mar 2026
Phase 1Ended 26 Mar 2026
Completed14 participants
NCT00979238
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
No phaseEnded 30 Jan 2026
No phaseEnded 5 Jan 2026
Completed35 participants
NCT07339410
Physiotherapy to Improve Balance and Walking Capacity in Hemophilia
No phaseEnded 31 Dec 2025
Completed10 participants
NCT06535971
Individualized Exercise Combined With Manual Therapy in Severe Hemophilia Patients With Polyarthropathy
No phaseEnded 31 Dec 2025
Withdrawn before start0 participants
NCT06634836
Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B
Reason given: Business decision
Phase 3Ended 19 Dec 2025
No phaseEnded 15 Dec 2025
Completed146 participants
NCT07110675
Central Sensitisation in Patients With Haemophilia and Degenerative Arthropathy
No phaseEnded 30 Nov 2025
Completed190 participants
NCT06191068
Canadian CHO-KLAT/H-FIT Study - Quality of Life of, and Burden of Caring for, Persons With Hemophilia
No phaseEnded 4 Nov 2025
Completed329 participants
NCT06574984
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
No phaseEnded 27 Oct 2025
Completed14 participants
NCT06580340
Effectiveness of an Adapted Physical Activity Program for Subjects Suffering From Haemophilia
No phaseEnded 20 Oct 2025
Phase 3Ended 19 Oct 2025
Completed124 participants
NCT06142552
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
No phaseEnded 14 Oct 2025
Completed150 participants
NCT05044845
Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy
No phaseEnded 30 Sept 2025
Completed28 participants
NCT03875547
Post-marketing Surveillance (Use Result Surveillance) With Refixia®
No phaseEnded 18 Sept 2025
Stopped early3 participants
NCT06530030
Goal Attainment and Physical Activity in People With Hemophilia A
Reason given: Early discontinuation based on sponsor decision not driven by any safety concerns.
No phaseEnded 9 Sept 2025
Phase 3Ended 29 Aug 2025
Completed85 participants
NCT03315455
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
No phaseEnded 20 Aug 2025
Completed300 participants
NCT06879392
Examination of Physiotherapists' Knowledge, Awareness and Competence on Physical Activity and Exercise in Hemophilia Patients
No phaseEnded 25 Jul 2025
Completed34 participants
NCT06636565
Comparison of Pulmonary Function, Exercise Capacity, and Physical Activity Level Between Children With Hemophilia and Healthy Controls
No phaseEnded 18 Jul 2025
Completed71 participants
NCT05248594
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
Phase 3Ended 7 Jul 2025
Stopped early2 participants
NCT05695391
Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery
Reason given: Feasibility considerations - extended timelines to complete recruitment
No phaseEnded 30 Jun 2025
Phase 3Ended 25 Jun 2025
Completed36 participants
NCT05147662
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
- Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study. · European journal of haematology, 2026
- Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study. · European journal of haematology, 2026
No phaseEnded 2 Jun 2025
No phaseEnded 2 Jun 2025
Completed36 participants
NCT04805021
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
No phaseEnded 1 Jun 2025
Completed46 participants
NCT05879549
Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises Patient With Hemophilia
Phase 3Ended 8 May 2025
Completed22 participants
NCT04323098
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
No phaseEnded 5 May 2025
Phase 3Ended 29 Apr 2025
Completed188 participants
NCT03938792
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
- Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. · Blood, 2026
- Clinical Pharmacokinetics and Pharmacodynamics of Marstacimab, an Anti-tissue Factor Pathway Inhibitor Monoclonal Antibody, in Adolescent and Adult Participants with Hemophilia. · Clinical pharmacokinetics, 2026
Phase 2Ended 27 Mar 2025
Completed5 participants
NCT06144086
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
Phase 3Ended 19 Mar 2025
Completed67 participants
NCT03569891
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
- Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. · The New England journal of medicine, 2026
No phaseEnded 1 Feb 2025
Phase 3Ended 29 Jan 2025
Stopped early15 participants
NCT06568302
The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
Reason given: Study terminated due to business and strategic decision.
Phase 2Ended 16 Jan 2025
No phaseEnded 31 Dec 2024
No phaseEnded 24 Dec 2024
Not medical advice. fetched 7 Nov 2026